Redox-Responsive Peptide Coacervates Advance mRNA Delivery

Study Background and Research Question

Messenger RNA (mRNA) therapeutics have opened transformative avenues in vaccine development, cancer immunotherapy, and gene editing. Yet, the clinical realization of these technologies is hampered by the intrinsic instability of mRNA, susceptibility to enzymatic degradation, and the challenges of delivering RNA across cell membranes without triggering unwanted immune responses. Lipid nanoparticles (LNPs) dominate the current clinical landscape, but concerns about biosafety, inefficient endosomal escape, and manufacturing complexity have motivated the search for alternative delivery systems. Peptide-based vectors, particularly those capable of liquid–liquid phase separation (LLPS), are increasingly attractive for their biocompatibility, functional tunability, and potential for stimuli-responsive control. The central research question addressed by Ren et al. is whether a rationally designed, redox-responsive peptide coacervate system can overcome the dual challenges of mRNA protection and cytosolic release, thereby advancing the safety and efficacy of mRNA delivery platforms.

Key Innovation from the Reference Study

The principal innovation in this work is the engineering of a minimalist, single-component peptide system (HBpep-SS4) that encapsulates mRNA within phase-separated coacervates and enables stimulus-triggered release via redox-responsive disulfide bonds. The design embeds tandem cysteine residues into the peptide's primary sequence, allowing for controlled formation and reduction of disulfide crosslinks. Unlike approaches requiring complex postsynthetic modifications or protein conjugation, HBpep-SS4 is chemically defined and synthesized using standard peptide chemistry, minimizing the risk of toxic byproducts and simplifying manufacturing. This intrinsic environmental responsiveness—encoded directly in the peptide backbone—enables the coacervate to remain stable extracellularly and to selectively disassemble in the reductive cytosolic environment, where glutathione concentrations are elevated. Such a design tightly integrates structure, function, and stimulus-responsiveness, marking a significant step forward over conventional peptide-based mRNA delivery vehicles.

Methods and Experimental Design Insights

The study systematically characterizes the phase separation behavior and redox sensitivity of HBpep-SS4 compared to both the parent peptide (HBpep) and other cysteine-modified variants (SS1–SS3). Key parameters such as peptide concentration, pH, and ionic strength were mapped to construct detailed phase diagrams, revealing the optimal conditions for coacervate formation. The encapsulation efficiency for various RNA species—including linear, circular, and self-amplifying RNAs (up to ~9700 nucleotides)—was quantified, with >95% encapsulation achieved. Time-dependent turbidity and optical microscopy confirmed the coacervate stability and redox-triggered disassembly in the presence of physiological glutathione concentrations (1 mM). Cellular uptake and trafficking studies, using enhanced green fluorescent protein (EGFP) mRNA as a reporter, elucidated the endocytic pathways involved: HBpep-SS4 is primarily internalized via phagocytosis and notably bypasses classical endosomal trafficking, facilitating direct cytosolic RNA release and circumventing one of the major bottlenecks in mRNA delivery.

Protocol Parameters

• Peptide concentration for coacervate formation: 0.1–4 mg/mL HBpep-SS4 in buffer, optimized at 1 mg/mL for most encapsulation assays.
• Buffer conditions: 0.1 M NaCl, pH range 6.0–8.0, with optimal phase separation observed near physiological pH (7.0–7.5).
• mRNA encapsulation: Mix peptide and RNA at a 1:1 mass ratio, incubate for 5–10 minutes at room temperature.
• Redox-triggered release: Add 1 mM glutathione to simulate cytosolic conditions for in vitro release assays.
• Transfection evaluation: Use EGFP mRNA or SpCas9 mRNA/sgRNA as functional readouts in target cell lines.

Core Findings and Why They Matter

The HBpep-SS4 coacervate system demonstrated several critical advances over previous delivery approaches:

• High RNA encapsulation efficiency: >95% of mRNA was stably integrated into the coacervate matrix, preserving integrity and protecting from nucleases.
• Efficient cytosolic release: Redox-triggered disassembly in the presence of glutathione enabled rapid release of mRNA into the cytoplasm, bypassing endosomal entrapment—a major hurdle for many nanoparticle systems.
• Broad RNA compatibility: The system effectively delivered diverse RNA species, including self-amplifying RNA and long mRNA constructs.
• High functional transfection: Delivery of SpCas9 mRNA and sgRNA achieved up to 86.0% EGFP gene disruption and 72.5% editing at the HBB locus, demonstrating robust genome editing capabilities.
• Biocompatibility and safety: The use of a chemically defined, single-component peptide reduced risk of immunogenicity and cytotoxicity typically associated with more complex carriers.

Together, these results indicate that rationally designed, redox-responsive peptide coacervates can bridge the gap between high-efficiency delivery and biosafety, a balance that has long limited the translation of mRNA therapeutics.

Comparison with Existing Internal Articles

The findings of Ren et al. provide a compelling benchmark for next-generation non-viral mRNA delivery systems. Recent internal articles, such as "EZ Cap™ EGFP mRNA (5-moUTP): Capped mRNA for High-Fidelity Expression", have emphasized the importance of capped mRNA with Cap 1 structure and chemically stabilized nucleotides (e.g., 5-moUTP) for maximizing translation efficiency and minimizing innate immune activation. These articles highlight the role of advanced mRNA engineering in improving both stability and translational output.

While the reference study focuses on the delivery vector itself, internal resources such as "EZ Cap EGFP mRNA 5-moUTP: Optimizing mRNA Delivery and Expression" provide practical workflows for combining stable, low-immunogenic mRNA reporters with innovative delivery systems to assess transfection efficiency and cell viability. The synergy between peptide-based carriers like HBpep-SS4 and robust reporter mRNAs (such as EGFP with 5-methoxyuridine modifications) can offer a holistic solution for translation efficiency assays and in vivo imaging with fluorescent mRNA reporters.

Limitations and Transferability

Despite its promise, the HBpep-SS4 system presents several limitations. While in vitro and cell-based assays confirm robust mRNA delivery and genome editing, the study does not extensively address in vivo pharmacokinetics, biodistribution, or long-term safety, which are critical for clinical translation. The peptide’s redox-responsiveness is tuned to cytosolic glutathione concentrations, but physiological variability in different tissue environments may impact release kinetics. Further, while the approach achieves broad nucleic acid compatibility, its performance with highly structured or chemically modified mRNAs (such as those with extensive base modifications) remains to be systematically explored. Thus, while the platform advances the field, additional work is necessary to validate its scalability, manufacturability, and in vivo efficacy across diverse biological models.

Research Support Resources

To facilitate experimental workflows that parallel those described by Ren et al., researchers can utilize synthetic, stable reporter mRNAs such as EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016). This enhanced green fluorescent protein mRNA incorporates a Cap 1 structure and 5-methoxyuridine modifications, supporting sensitive evaluation of mRNA delivery for gene expression, translation efficiency, and suppression of RNA-mediated innate immune activation. When paired with advanced delivery systems—including peptide coacervates—such reporters enable reproducible, high-resolution quantification of transfection outcomes and in vivo imaging with fluorescent mRNA.